Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety of Different Doses of Indacaterol

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Placebo to Indacaterol
Drug: Indacaterol
Drug: Salmeterol
Drug: Placebo to Salmeterol

First Posted Date: 2010-03-02

Last Posted Date: 2011-08-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 511

Registration Number: NCT01079130

Locations: 🇺🇸
Novartis Investigative site, North Charleston, South Carolina, United States
🇺🇸
Novartis Investigator Site, Seattle, Washington, United States
🇺🇸
Novartis Investigative Site, Charleston, South Carolina, United States

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Phase 1

Completed

Conditions: Chronic Myeloid Leukemia
Acute Lymphoblastic Leukemia

Interventions: Drug: Nilotinib

First Posted Date: 2010-03-01

Last Posted Date: 2020-12-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 15

Registration Number: NCT01077544

Locations: 🇬🇧
Novartis Investigative Site, Bristol, United Kingdom

Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy

Phase 3

Terminated

Conditions: Lymphoma, Follicular

Interventions: Drug: Ofatumumab
Drug: Ofatumumab and Bendamustine infusions (Arm A)
Drug: Bendamustine infusion
Drug: Bendamustine infusion (Arm B)

First Posted Date: 2010-03-01

Last Posted Date: 2020-03-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 346

Registration Number: NCT01077518

Locations: 🇬🇧
Novartis Investigative Site, Uxbridge, United Kingdom

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

Phase 2

Completed

Conditions: Cancer

Interventions: Drug: GSK2118436
Drug: GSK1120212

First Posted Date: 2010-02-19

Last Posted Date: 2019-07-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 430

Registration Number: NCT01072175

Locations: 🇦🇺
Novartis Investigative Site, Heidelberg, Victoria, Australia

A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Phase 2

Completed

Conditions: Chronic Plaque-type Psoriasis

Interventions: Drug: AIN457
Drug: Placebo

First Posted Date: 2010-02-19

Last Posted Date: 2015-02-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 125

Registration Number: NCT01071252

Locations: 🇱🇻
Novartis Investigative Site, Riga, Latvia

Second Open Label Extension to Bridging Study CTBM100C2303

Phase 3

Completed

Conditions: Pseudomonas Aeruginosa
Pulmonary Infections

Interventions: Drug: Tobramycin inhalation powder

First Posted Date: 2010-02-17

Last Posted Date: 2021-06-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 49

Registration Number: NCT01069705

Locations: 🇿🇦
Novartis Investigative Site, Durban, South Africa

Safety and Efficacy of Multiple Doses of QAX028 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Placebo
Drug: QAX028
Drug: Tiotropium

First Posted Date: 2010-02-15

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 62

Registration Number: NCT01068613

Locations: 🇺🇸
Spartanburg Medical Research, 485 Simuel Road, Spartanburg, South Carolina, United States
🇺🇸
Advanced Clinical Research Institute, 1211 W. La Palma Ave, Anaheim, California, United States
🇺🇸
New Orleans Center for Clinical Research - Knoxville, 1928 Alcoa Highway, Knoxville, Tennessee, United States

and more 1 locations

Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients

Phase 1

Completed

Conditions: Ovarian Cancer
Endometrium Cancer
Breast Cancer
Colon Cancer

Interventions: Drug: BKM120

First Posted Date: 2010-02-15

Last Posted Date: 2020-12-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 107

Registration Number: NCT01068483

Locations: 🇺🇸
Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(4), Nashville, Tennessee, United States
🇪🇸
Novartis Investigative Site, Barcelona, Cataluna, Spain

Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.

Phase 1

Terminated

Conditions: Chronic Myeloid Leukemia (CML)
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN)

Interventions: Drug: Gleevec/Glivec

First Posted Date: 2010-02-10

Last Posted Date: 2012-03-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 3

Registration Number: NCT01066468

Locations: 🇷🇺
Novartis Investigative Site, Moscow, Russian Federation

Efficacy, Safety, Tolerability, and Pharmacokinetics of Sotrastaurin Combined With Tacrolimus vs. a Mycophenolic Acid-tacrolimus Regimen in Renal Transplant Patients

Phase 2

Completed

Conditions: Renal Transplantation

Interventions: Drug: sotrastaurin (Dose 1) + tacrolimus + standard of care medications
Drug: sotrastaurin (Dose 2) + tacrolimus + standard of care medications
Drug: sotrastaurin (Dose 3) + tacrolimus + standard of care medications
Drug: mycophenolic acid + tacrolimus + standard of care medications

First Posted Date: 2010-02-08

Last Posted Date: 2020-12-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 298

Registration Number: NCT01064791

Locations: 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy